Full Coverage
F.D.A. Approves New Obesity Drug That Will Compete With Wegovy
By Gina Kolata
Top news
All coverage
Eli Lilly's Zepbound has a strong shot of being the biggest drug of all time: Guggenheim's Fernandez
Mounjaro weight loss jab authorised in UK
By Michelle Roberts
FDA Approves Tirzepatide for Treating Obesity
By Miriam E. Tucker
Lilly weight-loss drug gets US, UK approval to rival Wegovy
By Patrick Wingrove & Bhanvi Satija
Zepbound is Eli Lilly’s new weight loss drug: What to know
By Berkeley Lovelace & Berkeley Lovelace Jr.
Zepbound weight loss drug approved by FDA
By Laura Baisas
FDA approves new obesity drug from Eli Lilly named Zepbound
By Daniel Gilbert & David Ovalle
Tirzepatide Wins FDA Approval for Weight Loss
By Kristen Monaco
FDA approves the active ingredient in Mounjaro to help people with obesity lose weight, named Zepbound
By Sony Salzman & Mary Kekatos
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and Wegovy
By Berkeley Lovelace & Berkeley Lovelace Jr.
FDA approves Eli Lilly's tirzepatide for weight loss, paving way for wider use of blockbuster drug
By Annika Kim Constantino
FDA approves potent Eli Lilly obesity drug, Zepbound - STAT
By Elaine Chen & Damian Garde
What is Zepbound? The latest FDA-approved weight-loss drug.
By Lindsey Bever & Teddy Amenabar
FDA approves blockbuster Eli Lilly drug for weight loss
By Nathaniel Weixel